Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: Results of the LEGEND-A pilot study.
Spiliotis II. et al, (2022), Diabetes Obes Metab, 24, 1671 - 1675
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance.
Hamblin R. et al, (2022), Lancet Diabetes Endocrinol, 10, 581 - 588
Low-dose treatment with sulfonylureas improves hyperglucagonemia after a glucose challenge in HNF1A-MODY individuals and Hnf1a(-/-) mice
Saponaro C. et al, (2022), DIABETOLOGIA, 65, S162 - S162
HNF1A Deficiency Leads to Perturbed Glucagon Secretion in Humans
Saponaro C. et al, (2020), DIABETES, 69
Somatostatin secretion by Na+-dependent Ca2+-induced Ca2+ release in pancreatic delta-cells.
Vergari E. et al, (2020), Nat Metab, 2, 32 - 40
The Use of Empagliflozin and Dulaglutide Improves Metabolic and Glycemia Outcomes in a Real-World Primary Care Setting
Spiliotis I. and Gallen IW., (2020), DIABETES, 69
Loss of ZnT8 function protects against diabetes by enhanced insulin secretion.
Dwivedi OP. et al, (2019), Nat Genet, 51, 1596 - 1606
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
Vergari E. et al, (2019), Nat Commun, 10
Electrophysiological properties of human beta-cell lines EndoC-βH1 and -βH2 conform with human beta-cells.
Hastoy B. et al, (2018), Sci Rep, 8
Does Islet Size Really Influence Graft Function After Clinical Islet Transplantation?
Hughes SJ. et al, (2018), Transplantation, 102, 1857 - 1863
α-cell glucokinase suppresses glucose-regulated glucagon secretion.
Basco D. et al, (2018), Nat Commun, 9
δ-cells and β-cells are electrically coupled and regulate α-cell activity via somatostatin.
Briant LJB. et al, (2018), J Physiol, 596, 197 - 215
Loss of ZnT8 function protects against diabetes by enhanced insulin secretion
Dwivedi OP. et al, (2018)
Islet/stem cell transplantation – what's new?
Spiliotis I. and Johnson PRV., (2017), Paediatrics and Child Health (United Kingdom), 27, 181 - 186
Glucagon secretion in type 2 diabetes: results of the pilot clinical trial "Low dosE GlibENclamide in Diabetes - part A (LEGEND-A)"
Spiliotis II. et al, (2017), DIABETOLOGIA, 60, S29 - S29
Reversible changes in pancreatic islet structure and function produced by elevated blood glucose.
Brereton MF. et al, (2014), Nat Commun, 5
Reversible changes in pancreatic islet structure and function produced by elevated blood glucose
Brereton MF. et al, (2014), DIABETOLOGIA, 57, S93 - S93
The Emery-Dreifuss muscular dystrophy associated-protein emerin is phosphorylated on serine 49 by protein kinase A.
Roberts RC. et al, (2006), FEBS J, 273, 4562 - 4575